NDRA

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.

Wall Street analysts forecast NDRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NDRA is 38.00 USD with a low forecast of 38.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

ENDRA Life Sciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

ENDRA Life Sciences Inc. EPS for the last quarter amounts to -2.10 USD, decreased -99.37 % YoY.

ENDRA Life Sciences Inc (NDRA) has 21 emplpoyees as of December 17 2025.

Today NDRA has the market capitalization of 5.76M USD.